Skip to Main Content
TABLE 1

Clinical characteristics of patient samples

SampleSex (M/F)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)Plasma glucose at 2 h OGTT (mmol/l)
Sibships      
 Diabetes/severe IGT sib 280/329 65 ± 10 29 ± 5 9.3 ± 3.3 14.3 ± 5.6 
 NGT sib 275/305 62 ± 10 26 ± 3 5.4 ± 0.4 6.0 ± 1.1 
Scandinavia C/C      
 Diabetes/severe IGT 252/219 60 ± 10 28 ± 5 9.8 ± 3.4 15.0 ± 5.3 
 NGT 254/217 60 ± 10 27 ± 4 6.2 ± 1.8 6.8 ± 2.8 
Canada C/C      
 Diabetes 70/57 53 ± 8 29 ± 5 6.4 ± 1.8 12.8 ± 2.1 
 NGT 70/57 52 ± 8 29 ± 4 5.1 ± 0.6 6.1 ± 1.1 
Sweden C/C      
 Diabetes/severe IGT 267/247 66 ± 12 28 ± 4 8.5 ± 2.5 15.5 ± 4.0 
 NGT 267/247 66 ± 12 28 ± 4 4.8 ± 0.6 ND 
SampleSex (M/F)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)Plasma glucose at 2 h OGTT (mmol/l)
Sibships      
 Diabetes/severe IGT sib 280/329 65 ± 10 29 ± 5 9.3 ± 3.3 14.3 ± 5.6 
 NGT sib 275/305 62 ± 10 26 ± 3 5.4 ± 0.4 6.0 ± 1.1 
Scandinavia C/C      
 Diabetes/severe IGT 252/219 60 ± 10 28 ± 5 9.8 ± 3.4 15.0 ± 5.3 
 NGT 254/217 60 ± 10 27 ± 4 6.2 ± 1.8 6.8 ± 2.8 
Canada C/C      
 Diabetes 70/57 53 ± 8 29 ± 5 6.4 ± 1.8 12.8 ± 2.1 
 NGT 70/57 52 ± 8 29 ± 4 5.1 ± 0.6 6.1 ± 1.1 
Sweden C/C      
 Diabetes/severe IGT 267/247 66 ± 12 28 ± 4 8.5 ± 2.5 15.5 ± 4.0 
 NGT 267/247 66 ± 12 28 ± 4 4.8 ± 0.6 ND 

Data are presented as means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an OGTT. IGT, impaired glucose tolerance; IFG, impaired fasting glucose; NGT, normal glucose tolerance; C/C, case/control; ND, not done.

Close Modal

or Create an Account

Close Modal
Close Modal